Devyser Diagnostics AB (publ)

OM:DVYSR Stock Report

Market Cap: SEK 1.0b

Devyser Diagnostics Valuation

Is DVYSR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of DVYSR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: DVYSR (SEK60.7) is trading below our estimate of future cash flow value (SEK589.1)

Significantly Below Future Cash Flow Value: DVYSR is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DVYSR?

Key metric: As DVYSR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for DVYSR. This is calculated by dividing DVYSR's market cap by their current earnings.
What is DVYSR's PE Ratio?
PE Ratio67.9x
EarningsSEK 15.00m
Market CapSEK 1.02b

Price to Earnings Ratio vs Peers

How does DVYSR's PE Ratio compare to its peers?

The above table shows the PE ratio for DVYSR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average14.2x
SPRINT Sprint Bioscience
5.1xn/aSEK 429.4m
SANION Saniona
8.4xn/aSEK 1.8b
NICA Nanologica
6.8xn/aSEK 163.1m
BIOG B BioGaia
36.6x18.17%SEK 12.1b
DVYSR Devyser Diagnostics
67.9x60.31%SEK 1.0b

Price-To-Earnings vs Peers: DVYSR is expensive based on its Price-To-Earnings Ratio (67.9x) compared to the peer average (14.2x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does DVYSR's PE Ratio compare vs other companies in the European Biotechs Industry?

7 CompaniesPrice / EarningsEstimated GrowthMarket Cap
DVYSR 67.9xIndustry Avg. 17.0xNo. of Companies8PE020406080100+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: DVYSR is expensive based on its Price-To-Earnings Ratio (67.9x) compared to the European Biotechs industry average (17x).

Price to Earnings Ratio vs Fair Ratio

What is DVYSR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DVYSR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio67.9x
Fair PE Ratio69.1x

Price-To-Earnings vs Fair Ratio: DVYSR is good value based on its Price-To-Earnings Ratio (67.9x) compared to the estimated Fair Price-To-Earnings Ratio (69.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DVYSR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 60.70
SEK 151.95
+150.32%
6.51%SEK 164.74SEK 140.63n/a3
Jun ’27SEK 92.80
SEK 151.95
+63.73%
6.51%SEK 164.74SEK 140.63n/a3
May ’27SEK 94.00
SEK 151.95
+61.64%
6.51%SEK 164.74SEK 140.63n/a3
Apr ’27SEK 78.60
SEK 155.79
+98.21%
7.52%SEK 169.81SEK 139.85n/a4
Mar ’27SEK 90.20
SEK 155.79
+72.72%
7.52%SEK 169.81SEK 139.85n/a4
Feb ’27SEK 104.00
SEK 152.71
+46.84%
6.37%SEK 163.26SEK 138.25n/a4
Jan ’27SEK 114.20
SEK 156.12
+36.71%
6.31%SEK 169.01SEK 144.26n/a4
Dec ’26SEK 112.80
SEK 156.23
+38.50%
6.30%SEK 169.18SEK 144.41n/a4
Nov ’26SEK 129.80
SEK 170.81
+31.59%
7.27%SEK 190.68SEK 160.10n/a4
Oct ’26SEK 138.00
SEK 170.83
+23.79%
7.09%SEK 190.07SEK 158.27n/a4
Sep ’26SEK 151.60
SEK 170.83
+12.69%
7.09%SEK 190.07SEK 158.27n/a4
Aug ’26SEK 147.00
SEK 172.06
+17.05%
6.67%SEK 190.54SEK 160.25n/a4
Jul ’26SEK 126.00
SEK 162.27
+28.79%
11.78%SEK 191.98SEK 138.62SEK 83.504
Jun ’26SEK 105.20
SEK 160.83
+52.88%
12.76%SEK 192.09SEK 135.10SEK 92.804
May ’26SEK 102.00
SEK 163.02
+59.82%
11.48%SEK 193.16SEK 142.44SEK 94.004
Apr ’26SEK 102.00
SEK 163.90
+60.69%
9.77%SEK 184.71SEK 140.66SEK 78.604
Mar ’26SEK 126.00
SEK 165.96
+31.71%
11.39%SEK 191.31SEK 138.27SEK 90.204
Feb ’26SEK 129.50
SEK 164.90
+27.34%
10.86%SEK 192.12SEK 142.06SEK 104.004
Jan ’26SEK 118.50
SEK 158.68
+33.91%
13.10%SEK 192.09SEK 139.92SEK 114.204
Dec ’25SEK 130.00
SEK 158.61
+22.01%
13.06%SEK 191.94SEK 140.05SEK 112.804
Nov ’25SEK 138.50
SEK 156.93
+13.31%
14.13%SEK 192.01SEK 136.07SEK 129.804
Oct ’25SEK 128.50
SEK 157.74
+22.76%
14.63%SEK 191.68SEK 133.45SEK 138.004
Sep ’25SEK 113.50
SEK 128.66
+13.36%
3.09%SEK 134.20SEK 125.04SEK 151.603
Aug ’25SEK 112.50
SEK 131.40
+16.80%
2.29%SEK 134.40SEK 128.39SEK 147.002
Jul ’25SEK 110.00
SEK 121.86
+10.78%
1.56%SEK 123.76SEK 119.96SEK 126.002
SEK 151.95
Fair Value
60.1% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 11:36
End of Day Share Price 2026/07/03 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Devyser Diagnostics AB (publ) is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Erik HultgårdCarnegie Investment Bank AB
Erik HultgårdDNB Carnegie
Ludvig LundgrenNordea Markets